NASDAQ · ALZN
Healthcare · Biotechnology
$1.72
Up+$0.02 (+1.18%)
Updated Sep 12, 2026, 6:41 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ALZN closed at $1.72 after 20 trading sessions, up 10.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.67 | $1.76 | $1.59 | $1.72 | 393.65K |
| Sep 10, 2026 | $1.67 | $1.70 | $1.5757 | $1.70 | 9.49K |
| Sep 9, 2026 | $1.69 | $1.73 | $1.645 | $1.68 | 29.6K |
| Sep 8, 2026 | $1.66 | $1.7166 | $1.62 | $1.68 | 31.19K |
| Sep 4, 2026 | $1.70 | $1.73 | $1.65 | $1.66 | 63.18K |
| Sep 3, 2026 | $1.65 | $1.72 | $1.65 | $1.70 | 128.25K |
| Sep 2, 2026 | $1.65 | $1.70 | $1.565 | $1.70 | 101.1K |
| Sep 1, 2026 | $1.615 | $1.68 | $1.615 | $1.6368 | 23.3K |
| Aug 31, 2026 | $1.655 | $1.655 | $1.51 | $1.60 | 37.77K |
| Aug 28, 2026 | $1.64 | $1.72 | $1.64 | $1.66 | 242.13K |
| Aug 27, 2026 | $1.67 | $1.67 | $1.65 | $1.665 | 39.92K |
| Aug 26, 2026 | $1.59 | $1.67 | $1.55 | $1.67 | 128.31K |
| Aug 25, 2026 | $1.53 | $1.65 | $1.5012 | $1.60 | 122.09K |
| Aug 24, 2026 | $1.51 | $1.58 | $1.41 | $1.55 | 133.88K |
| Aug 21, 2026 | $1.57 | $1.5984 | $1.49 | $1.56 | 244.13K |
| Aug 20, 2026 | $1.56 | $1.67 | $1.5318 | $1.63 | 486.2K |
| Aug 19, 2026 | $1.50 | $1.60 | $1.50 | $1.52 | 95.13K |
| Aug 18, 2026 | $1.52 | $1.5763 | $1.51 | $1.52 | 37.53K |
| Aug 17, 2026 | $1.5314 | $1.59 | $1.4807 | $1.58 | 118.65K |
| Aug 14, 2026 | $1.46 | $1.55 | $1.445 | $1.55 | 87.58K |
The latest Smart Investors Daily articles mentioning ALZN.
ALZN research
Company profile and research snapshot.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | Ascendiant Capital | Buy | — |
| Dec 22, 2025 | Ascendiant Capital | Buy | — |
| Sep 25, 2025 | Ascendiant Capital | Buy | — |
| Aug 21, 2025 | Ascendiant Capital | Buy | — |
| Mar 17, 2025 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 10, 2026
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of $(1.28) per share from
Benzinga · Aug 21, 2026
-SEC Filing
Yahoo · Aug 20, 2026
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting resting-state functional magnetic resonance imaging ("fMRI") findings for AL001, Alzamend's novel organic lithium salt, has been accepted for poster presentat
Benzinga · Aug 20, 2026
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALZN.
